Better Health for All

Beam Therapeutics' core business is entirely dedicated to developing precision genetic medicines for serious diseases. Clinical trials for BEAM-101 in sickle cell disease demonstrated robust and durable increases in fetal hemoglobin and reductions in sickle hemoglobin in 17 patients, leading to resolution of anemia.

Similarly, BEAM-302 for alpha-1 antitrypsin deficiency showed the ability to correct a disease-causing mutation, resulting in a 78% reduction in mutant enzyme and an almost tripled increase in total functional enzyme at the highest dose. These outcomes represent revolutionary health benefits for severe genetic conditions. The company is primarily in the research and development phase and has no commercial products with established negative health outcomes, with its entire focus on positive health impact. Regarding safety, the BEAM-101 trial reported one patient death four months post-treatment due to respiratory failure, which was deemed likely related to busulfan conditioning, not BEAM-101 itself. Common adverse events were consistent with the conditioning regimen. The BEAM-302 trial reported a 'promising safety profile' without specific adverse event rates. Given the death was attributed to the conditioning regimen and not the company's product, and no adverse event rates per million users are provided for the product itself, there is insufficient data to score the safety record beyond 'Not applicable'. The company is seeking $500 million in financing to advance its base editing programs, including research, development, and pre-commercial activities for BEAM-302 and BEAM-101.

Fair Money & Economic Opportunity

Beam Therapeutics Inc. is a biotechnology company focused on genetic medicines and research and development activities.

The provided articles detail the company's clinical progress, financial results, and general ESG data. None of the articles contain any information or specific data points related to the company offering lending, deposit, or other financial services to consumers, nor do they mention any initiatives concerning financial inclusion, fair lending, or wealth building for underserved populations. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are scored as '0: Not applicable' because the company's core business lies outside financial services and it does not offer relevant financial products or services.

Fair Pay & Worker Respect

Beam Therapeutics Inc. reported a CEO-to-median employee pay ratio of 25:1 for the fiscal year ending 2024.

As of December 31, 2024, no team members were represented by a labor union or covered by a collective bargaining agreement. The company offers 100% employer-funded health insurance coverage for all full-time employees. Beam Therapeutics has not had any fines or violations in the past two years. Employee surveys indicate that 77% of employees would recommend working at the company, and the employee retention rate target is greater than 85%.

Kind to Animals

Beam Therapeutics explicitly uses in vivo animal models for preclinical studies and product candidate evaluation, including rodent models (NSG-PiZ mice and humanized PiZ rats) for BEAM-302 and non-human primates for other programs.

The company does not provide specific details on the usage of alternative testing methods, indicating a reliance on animal testing. The company's animal testing policy mentions the use of animal models and compliance with the United States Department of Agriculture’s Animal Welfare Act, if applicable, but lacks further details on specific restrictions, reduction goals, or accountability beyond basic legal compliance.

No War, No Weapons

Beam Therapeutics Inc. is a biotechnology company focused on genetic medicines. The provided articles contain no evidence of the company's involvement in arms manufacturing, military contracts, or conflict facilitation. There is no indication of revenue derived from arms or defense contracts, nor any R&D investment in dual-use technologies with military applications.

While the company's technologies are noted as potentially adaptable beyond human therapeutics, no such applications are discussed or endorsed, and there is no mention of military or weapons applications. Consequently, there is no defense business for the board to oversee. The company's internal policy prohibits weapons in the workplace, which is a general HR policy and not an ethical red line for product-related military engagement. Furthermore, the company's monitoring of employee electronic systems is for internal purposes and does not indicate involvement in external intelligence or surveillance contracts.

Planet-Friendly Business

The provided articles, which include ESG summaries from Sustainalytics and Yahoo Finance, and an S&P Global ESG page, explicitly state a lack of detailed quantitative sustainability metrics for Beam Therapeutics Inc.

No specific, concrete data points are available for any of the Planet-Friendly Business KPIs, such as emissions, renewable energy use, water consumption, waste diversion, or environmental compliance violations. Therefore, an assessment against the defined rubric is not possible.

Zero Waste & Sustainable Products

The provided articles do not contain any specific, quantitative data points or initiatives related to Beam Therapeutics Inc.'s waste management, product recyclability, packaging sustainability, or other zero-waste and sustainable product metrics.

Both articles explicitly state a lack of relevant information and significant data gaps regarding the company's performance in this area.